HOME > BUSINESS
BUSINESS
- Toho Pharmaceutical to Acquire Shouei in January 2012
September 12, 2011
- Astellas to Transfer Distribution Rights for Targocid, Maalox to sanofi-aventis
September 12, 2011
- Toyama Chemical, Eisai Resubmit NDA for RA Treatment T-614
September 12, 2011
- Pfizer’s Novel NSCLC Treatment Crizotinib Receives Approval in US
September 12, 2011
- Bayer’s Alpharadin to Be Granted Fast Track Review Status from FDA
September 12, 2011
- Ethical Drugs Sales Rise 5.3% in 2nd Quarter: IMS Japan
September 12, 2011
- Market for Anti-RA Drugs to Exceed ¥300 Bil. in 2019: Fuji-Keizai
September 12, 2011
- Mizuho Forecasts Higher Sales, Lower Profits for 9 Major Domestic Drug Makers in FY2011
September 12, 2011
- Nomura Securities Raises Target Share Prices for 3 Drug Wholesalers
September 12, 2011
- Kissei Obtains Japan Rights for Anthracycline Extravasation Agent
September 12, 2011
- Astellas Licenses Fully-Human Antibody against Infectious Diseases from Evec
September 12, 2011
- Drug-only Warehouses at Haneda Airportto Start Full-scale Operations this Fall
September 12, 2011
- Former Employee of Regional Wholesaler Sanki Charged with Illegal Drug Sales
September 12, 2011
- More ADCs and Other Anticancer Drugs from Domestic Drug Makers Enter Late Stage Development
September 12, 2011
- Daiichi Sankyo to Transfer Part of R&D Function to Subsidiary
September 12, 2011
- Takeda Begins Domestic PII Clinical Trials for Leuplin Successor TAK-385
September 12, 2011
- Medinet Granted Patent on Cancer Antigen Peptide in 11 European Countries
September 12, 2011
- Helsinn Initiates Global PIII Program for Anamorelin
September 12, 2011
- Takara Bio to Supply Plasmid Vectors for iPS Cell Production to Kyoto University
September 12, 2011
- JAK Inhibitor May Be as Effective as Biologics at Lower Cost: Prof. Takeuchi of Keio University
September 12, 2011
ページ
In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…